All In Biotech

Drug Trial Radar · NCT03824392

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis

Last checked: Nov 19, 2026Latest source record: Jul 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

37

Actual

Start

Jan 29, 2019

Primary completion

Jun 29, 2021

Study completion Jun 29, 2021

Sponsor

Lead sponsor
aTyr Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Foundation for Sarcoidosis Research
First posted
Jan 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod in participants with pulmonary sarcoidosis undergoing a protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3 staggered multiple dose cohorts. Each eligible participant will participate in only one cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to efzofitimod (N=8) or placebo matched to efzofitimod (N=4).

Conditions

  • Pulmonary Sarcoidosis

Interventions

  • Efzofitimod 1.0 mg/kg or PlaceboBiological

    Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks

  • Efzofitimod 3.0 mg/kg or PlaceboBiological

    Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks

  • Efzofitimod 5.0 mg/kg or PlaceboBiological

    Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to Week 24

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • aTyr Investigative Site

    Northridge, California

  • National Jewish Health

    Denver, Colorado

  • aTyr Investigative Site

    Miami, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • aTyr Investigative Site

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Louisville

    Louisville, Kentucky

  • East Carolina University

    Greenville, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • UT Southwestern Medical Center

    Dallas, Texas

  • Inova Fairfax Medical Center

    Falls Church, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.